STATCenter·
STAT+: RevMed’s pancreatic cancer drug nears European approval
Following a green light from the FDA, European regulators have now recommended the approval of Revolution Medicines' Rasonque for pancreatic cancer.
Read at STAT →
Health · 1 sources covering this
STAT+: RevMed’s pancreatic cancer drug nears European approval
Following a green light from the FDA, European regulators have now recommended the approval of Revolution Medicines' Rasonque for pancreatic cancer.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/be596ccf39cc6aecaafa0dedcdadd8f895f11e4c" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: RevMed’s pancreatic cancer drug nears European approval"></iframe>
